Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Journal of the American College of Cardiology|September 5, 2015
Pediatric Appropriate Use Criteria Implementation Project: A Multicenter Outpatient Echocardiography Quality InitiativeRitu Sachdeva, Joseph Allen, Oscar J Benavidez, et al.
Congenital Heart Disease|March 21, 2013
Mechanical support as failure intervention in patients with cavopulmonary shunts (MFICS): rationale and aims of a new registry of mechanical circulatory support in single ventricle patientsJoseph W Rossano, Ronald K Woods, Stuart Berger, et al.
Cancer Research|July 31, 2019
Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian CancerStephen Shang, Jiekun Yang, Amir A Jazaeri, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Crystal structure of the human PRMT5:MEP50 complexStephen Antonysamy, Zahid Bonday, Robert M Campbell, et al.
Journal of Medicinal Chemistry|March 17, 2006
Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7Hong-yu Li, Yan Wang, Charles R Heap, et al.
British Journal of Haematology|April 10, 2008
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implicationsKenji Ishitsuka, Teru Hideshima, Paola Neri, et al.
Molecular Cancer Therapeutics|September 5, 2024
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in CancerRobinson Triboulet, Khikmet Sadykov, Darren M Harvey, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domainJ Scott Sawyer, Douglas W Beight, Karen S Britt, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor ActivityZahid Q Bonday, Guillermo S Cortez, Michael J Grogan, et al.
Journal of Medicinal Chemistry|September 5, 2003
Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domainJ Scott Sawyer, Bryan D Anderson, Douglas W Beight, et al.
Pageof 19